Other studies like studies by Offord,[15] and Rahi et al,[10] showed majority of the ill children were first born. Among different disorders, most of the children were having specific isolated phobia read me (19.6%), other non organic sleep disorders like sleep talking, bruxism etc (12.0%) and tension headache (11.5%). Deivasinagamini,[2] found prevalent psychiatric disorders to be conduct disorder (14.3%), enuresis (14.3%), mental retardation (2.9%) and hyperkinetic disorder (1.7%). In our study hyperkinetic disorder found in 6% of the students, enuresis in 4.5% and mental retardation in 1.5% of the students. In another study in 4-16 yr age group children by Srinath et al,[13] was preceded by enuresis (6.2%) followed by specific phobia (2.9%) and hyperkinetic disorder (1.6%) and stuttering (1.5%).

In view of the above discussion, it is concluded that it is imperative to carry out this type of epidemiological survey more in number and to follow up them longitudinally to understand the natural history of childhood and adolescent disorders. The results of the study have implications for clinical training, practice and policy initiatives. Integrating mental health into general health care, effective mass media coverage, networking between mental health-professionals and other health professionals, community-based health services and involvement of professionals from the education sector, would be essential. LIMITATIONS The study has been done in a small number of children where male children are significantly higher in number than female.

Cross sectional study should be followed by longitudinal study to find out the course and pattern of their disorder. Moreover, other socio-demographic entities should be searched for and compared to find out any possible correlation. Footnotes Source of Support: Nil. Conflict of Interest: None declared.
The concept of bioenhancers or biopotentiators is new to the modern science. It was first time reported by Bose in 1929, who described the increase in the antiasthmatic effects of vasaka (Adhatoda vasica) leaves by the addition of long pepper to it.[1] The development and consequent isolation of these molecules is considered as a scientific breakthrough. A bioenhancer is an agent capable of enhancing the bioavailability and efficacy of a drug with which it is co-administered, without any pharmacological activity of its own at the therapeutic dose used.

They tend to decrease the dose of active drug required for the optimal endpoint of the treatment strategy, bypassing the need to use injectable routes of drug administration to a larger extent, might help in overcoming the resistance to antimicrobials and saving the precious raw materials for the manufacturing of medicines. Such fixed drug combinations (FDCs) are GSK-3 economically viable too. The concept of bioenhancer is called Yogvahi in Ayurveda.